
STATUS UPDATE ON THE LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA

1. INTRODUCTION

Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in the following announcements:

- (a) the announcements of the Company between 13 December 2017 to 16 March 2021 in relation to the arbitration and enforcement proceedings by the Company against David Lin Kao Kun ("**David Lin**")¹ and
- (b) the announcements of the Company between 22 February 2017 to 26 February 2021 in relation to the Company's on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) ("**Weixin**")²;

(collectively, the "**Previous Announcements**").

2. PROCEEDINGS COMMENCED BY WEIXIN

2.1 The Company refers to the Previous Announcements, in particular, the announcements dated 23 August 2018, 3 November 2019, 25 November 2019, 12 December 2019, 30 June 2020, 27 August 2020, 25 September 2020 and 16 March 2021 in relation to the following events:

- (a) The legal proceedings commenced by Weixin (which was then controlled by David Lin) against the Company's subsidiaries, Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) and Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) for a declaration that a land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015, in relation a plot of land estimated at 22,680.9 square metres at No. 20 Changjiang North Road, New District, Wuxi Jiangsu Province (the "**Wuxi Land**"), is void (the "**Land Litigation**").
- (b) On 22 November 2019, the Wuxi Xinwu District Court dismissed Weixin's application in the Land Litigation. The Court found that the land transfer agreement is legitimate and binding on all relevant parties.

¹ Please refer to the Company's announcements dated 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019, 29 April 2019, 31 May 2019, 26 June 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 30 October 2019, 3 November 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 22 April 2020, 29 April 2020, 29 May 2020, 30 June 2020, 30 July 2020, 27 August 2020, 31 August 2020; 29 September 2020, 29 October 2020, 30 November 2020, 31 December 2020, 29 January 2021, 26 February 2021 and 16 March 2021.

² Please refer to the Company's announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 14 October 2019, 30 October 2019, 25 November 2019, 29 November 2019, 12 December 2019 and 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 29 May 2020, 30 June 2020, 30 July 2020, 31 August 2020; 29 September 2020, 29 October 2020, 30 November 2020, 31 December 2020, 29 January 2021 and 26 February 2021.

- (c) On 4 December 2019, Weixin appealed against the Wuxi Judgment to the Wuxi Intermediate Court (the “**Land Litigation Appeal**”).
- (d) On 1 November 2019, the Company obtained an order to appoint Chan Pui Sze, Mak Hau Yin and Wong Teck Meng of Briscoe Wong Advisory Limited, as receivers (the “**Receivers of HSIL**”) over David Lin’s interests in the shares in Healthcare Solution Investment Limited (“**HSIL**”).
- (e) On 22 May 2020, Weixin (under control of the Receivers of HSIL) applied to withdraw the Land Litigation Appeal. Prior to the Land Litigation Appeal hearing on 5 June 2020, Wuxi Yilin Real Estate sought a stay of the appeal, pending the conclusion of the Weixin Control Dispute (as defined below).
- (f) The Land Litigation Appeal was stayed pending the outcome of separate legal proceedings commenced by Weixin (under control of the Receivers of HSIL) against David Lin and Chiang Hui-Hua before the Shanghai Pudong Court (referred to as “**Weixin Control Dispute**” in the Previous Announcements). In these proceedings:
 - (i) Weixin sought an order that David Lin and Chiang Hui-Hua return, *inter alia*, Weixin’s business license and company stamp on the basis that Chiang Hui-Hua is no longer the legal representative of Weixin.
 - (ii) On 19 August 2020, the Shanghai Pudong Court issued a judgment in favour Weixin ordering Chiang Hui-Hua to return, *inter alia*, the business licenses and company stamp to Weixin. On 24 September 2020, the Company was informed by the Receivers that David Lin has appealed against the Shanghai Pudong Court’s decision.
 - (iii) On 15 March 2021, the Company was informed by the Receivers of HSIL that the Shanghai First Intermediate Court has dismissed David Lin’s appeal, with costs to be borne by David Lin. The Shanghai First Intermediate Court noted that the board of directors of HSIL (i.e. the sole shareholder of Weixin) had passed a valid board resolution to remove Chiang Hui-Hua as Weixin’s legal representative, executive director and general manager. As such, Chiang Hui-Hua no longer had the legal right since 27 November 2019 to retain Weixin’s business license and company stamp.

- 2.2 On 22 March 2021, the Company was informed by the Receivers of HSIL that the Wuxi Intermediate Court has issued a judgment on 18 March 2021 accepting Weixin’s application to withdraw the Land Litigation Appeal.

The effect of the Court’s judgment is that the decision of the Wuxi Xinwu District Court dated 22 November 2019 is final and binding on all parties. As mentioned above, in that judgment, the Court found that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015, in relation to the Wuxi Land, is legitimate and binding on all parties. In other words, the Company’s subsidiary - Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) is the rightful and legal owner of the Wuxi Land, and there are no pending legal challenges in relation to the ownership of Wuxi Land.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
22 March 2021

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Gillian Goh, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.